Article Correctness Is Author's Responsibility: DOD funding helps expand study of investigational drug to prevent ARDS in COVID

(University of Texas Health Science Center at Houston) Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at UTHealth.